Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Inhibrx Biosciences (INBX) EBIT (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed EBIT for 3 consecutive years, with -$30.9 million as the latest value for Q4 2025.

  • Quarterly EBIT rose 38.06% to -$30.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$135.0 million through Dec 2025, up 59.26% year-over-year, with the annual reading at -$135.0 million for FY2025, 59.26% up from the prior year.
  • EBIT for Q4 2025 was -$30.9 million at Inhibrx Biosciences, up from -$33.8 million in the prior quarter.
  • The five-year high for EBIT was -$27.4 million in Q2 2025, with the low at -$160.9 million in Q2 2024.
  • Average EBIT over 3 years is -$58.4 million, with a median of -$45.8 million recorded in 2023.
  • The sharpest move saw EBIT crashed 289.22% in 2024, then surged 82.98% in 2025.
  • Over 3 years, EBIT stood at -$88.3 million in 2023, then surged by 43.45% to -$49.9 million in 2024, then soared by 38.06% to -$30.9 million in 2025.
  • According to Business Quant data, EBIT over the past three periods came in at -$30.9 million, -$33.8 million, and -$27.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.